GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses

Oncolytic adenoviruses have become ideal agents in the path toward treating cancer. Such viruses have been engineered to conditionally replicate in malignant cells in which certain signaling pathways have been disrupted. Other than such oncolytic properties, the viruses need to activate the immune s...

Full description

Bibliographic Details
Main Authors: Firas Hamdan, Beatriz Martins, Michaela Feodoroff, Yvonne Giannoula, Sara Feola, Manlio Fusciello, Jacopo Chiaro, Gabriella Antignani, Mikaela Grönholm, Erkko Ylösmäki, Vincenzo Cerullo
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050121000140
id doaj-7934eb39ade74b8590b02cd788167162
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Firas Hamdan
Beatriz Martins
Michaela Feodoroff
Yvonne Giannoula
Sara Feola
Manlio Fusciello
Jacopo Chiaro
Gabriella Antignani
Mikaela Grönholm
Erkko Ylösmäki
Vincenzo Cerullo
spellingShingle Firas Hamdan
Beatriz Martins
Michaela Feodoroff
Yvonne Giannoula
Sara Feola
Manlio Fusciello
Jacopo Chiaro
Gabriella Antignani
Mikaela Grönholm
Erkko Ylösmäki
Vincenzo Cerullo
GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses
Molecular Therapy: Methods & Clinical Development
adenoviruses
Gibson Assembly
gene therapy
oncolytic viruses
molecular cloning
author_facet Firas Hamdan
Beatriz Martins
Michaela Feodoroff
Yvonne Giannoula
Sara Feola
Manlio Fusciello
Jacopo Chiaro
Gabriella Antignani
Mikaela Grönholm
Erkko Ylösmäki
Vincenzo Cerullo
author_sort Firas Hamdan
title GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses
title_short GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses
title_full GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses
title_fullStr GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses
title_full_unstemmed GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses
title_sort gamer-ad: a novel and rapid method for generating recombinant adenoviruses
publisher Elsevier
series Molecular Therapy: Methods & Clinical Development
issn 2329-0501
publishDate 2021-03-01
description Oncolytic adenoviruses have become ideal agents in the path toward treating cancer. Such viruses have been engineered to conditionally replicate in malignant cells in which certain signaling pathways have been disrupted. Other than such oncolytic properties, the viruses need to activate the immune system in order to sustain a long-term response. Therefore, oncolytic adenoviruses have been genetically modified to express various immune-stimulatory agents to achieve this. However, genetically modifying adenoviruses is very time consuming and labor intensive with the current available methods. In this paper, we describe a novel method we have called GAMER-Ad to genetically modify adenovirus genomes within 2 days. Our method entails the replacement of the gp19k gene in the E3 region with any given gene of interest (GOI) using Gibson Assembly avoiding the homologous recombination between the shuttle and the parental plasmid. In this manuscript as proof of concept we constructed and characterized three oncolytic adenoviruses expressing CXCL9, CXCL10, and interleukin-15 (IL-15). We demonstrate that our novel method is fast, reliable, and simple compared to other methods. We anticipate that our method will be used in the future to genetically engineer oncolytic but also other adenoviruses used for gene therapy as well.
topic adenoviruses
Gibson Assembly
gene therapy
oncolytic viruses
molecular cloning
url http://www.sciencedirect.com/science/article/pii/S2329050121000140
work_keys_str_mv AT firashamdan gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
AT beatrizmartins gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
AT michaelafeodoroff gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
AT yvonnegiannoula gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
AT sarafeola gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
AT manliofusciello gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
AT jacopochiaro gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
AT gabriellaantignani gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
AT mikaelagronholm gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
AT erkkoylosmaki gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
AT vincenzocerullo gameradanovelandrapidmethodforgeneratingrecombinantadenoviruses
_version_ 1724222177752907776
spelling doaj-7934eb39ade74b8590b02cd7881671622021-03-13T04:23:53ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012021-03-0120625634GAMER-Ad: a novel and rapid method for generating recombinant adenovirusesFiras Hamdan0Beatriz Martins1Michaela Feodoroff2Yvonne Giannoula3Sara Feola4Manlio Fusciello5Jacopo Chiaro6Gabriella Antignani7Mikaela Grönholm8Erkko Ylösmäki9Vincenzo Cerullo10Laboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandLaboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandLaboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandLaboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandLaboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandLaboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandLaboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandLaboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandLaboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, FinlandLaboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandLaboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland; Department of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University 24 Federico II, 80131 Naples, Italy; Corresponding author: Vincenzo Cerullo, Laboratory of Immunovirotherapy (IVTLab), Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.Oncolytic adenoviruses have become ideal agents in the path toward treating cancer. Such viruses have been engineered to conditionally replicate in malignant cells in which certain signaling pathways have been disrupted. Other than such oncolytic properties, the viruses need to activate the immune system in order to sustain a long-term response. Therefore, oncolytic adenoviruses have been genetically modified to express various immune-stimulatory agents to achieve this. However, genetically modifying adenoviruses is very time consuming and labor intensive with the current available methods. In this paper, we describe a novel method we have called GAMER-Ad to genetically modify adenovirus genomes within 2 days. Our method entails the replacement of the gp19k gene in the E3 region with any given gene of interest (GOI) using Gibson Assembly avoiding the homologous recombination between the shuttle and the parental plasmid. In this manuscript as proof of concept we constructed and characterized three oncolytic adenoviruses expressing CXCL9, CXCL10, and interleukin-15 (IL-15). We demonstrate that our novel method is fast, reliable, and simple compared to other methods. We anticipate that our method will be used in the future to genetically engineer oncolytic but also other adenoviruses used for gene therapy as well.http://www.sciencedirect.com/science/article/pii/S2329050121000140adenovirusesGibson Assemblygene therapyoncolytic virusesmolecular cloning